Shopping Cart 0
Cart Subtotal
USD 0

Dengue Fever-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Dengue Fever-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever-Pipeline Review, H1 2017, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape.

Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Dengue Fever-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 25, 22 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 5, 10 and 12 molecules, respectively.

Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 4

Dengue Fever-Overview 5

Dengue Fever-Therapeutics Development 6

Dengue Fever-Therapeutics Assessment 19

Dengue Fever-Companies Involved in Therapeutics Development 27

Dengue Fever-Drug Profiles 44

Dengue Fever-Dormant Projects 143

Dengue Fever-Discontinued Products 147

Dengue Fever-Product Development Milestones 148

Appendix 160


List Of Figure

List of Figures

Number of Products under Development for Dengue Fever, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Dengue Fever, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Dengue Fever-Pipeline by Abivax SA, H1 2017

Dengue Fever-Pipeline by Altravax Inc, H1 2017

Dengue Fever-Pipeline by Biological Mimetics Inc, H1 2017

Dengue Fever-Pipeline by Bioneer Corp, H1 2017

Dengue Fever-Pipeline by Biotron Ltd, H1 2017

Dengue Fever-Pipeline by Emergent BioSolutions Inc, H1 2017

Dengue Fever-Pipeline by Ennaid Therapeutics LLC, H1 2017

Dengue Fever-Pipeline by GeneSegues Inc, H1 2017

Dengue Fever-Pipeline by GlaxoSmithKline Plc, H1 2017

Dengue Fever-Pipeline by Globavir Biosciences Inc, H1 2017

Dengue Fever-Pipeline by Griffith University, H1 2017

Dengue Fever-Pipeline by Hawaii Biotech Inc, H1 2017

Dengue Fever-Pipeline by Humabs BioMed SA, H1 2017

Dengue Fever-Pipeline by Immunotope Inc, H1 2017

Dengue Fever-Pipeline by Indian Immunologicals Ltd, H1 2017

Dengue Fever-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Dengue Fever-Pipeline by Johnson & Johnson, H1 2017

Dengue Fever-Pipeline by Kineta Inc, H1 2017

Dengue Fever-Pipeline by Merck & Co Inc, H1 2017

Dengue Fever-Pipeline by Molplex Ltd, H1 2017

Dengue Fever-Pipeline by NanoViricides Inc, H1 2017

Dengue Fever-Pipeline by Novartis AG, H1 2017

Dengue Fever-Pipeline by NovaTarg Therapeutics Inc, H1 2017

Dengue Fever-Pipeline by Panacea Biotec Ltd, H1 2017

Dengue Fever-Pipeline by Plex Pharmaceuticals Inc, H1 2017

Dengue Fever-Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Dengue Fever-Pipeline by Sarepta Therapeutics Inc, H1 2017

Dengue Fever-Pipeline by SIGA Technologies Inc, H1 2017

Dengue Fever-Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Dengue Fever-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Dengue Fever-Pipeline by TechnoVax Inc, H1 2017

Dengue Fever-Pipeline by Themis Bioscience GmbH, H1 2017

Dengue Fever-Pipeline by Visterra Inc, H1 2017

Dengue Fever-Pipeline by VLP Therapeutics LLC, H1 2017

Dengue Fever-Dormant Projects, H1 2017

Dengue Fever-Dormant Projects, H1 2017 (Contd..1), H1 2017

Dengue Fever-Dormant Projects, H1 2017 (Contd..2), H1 2017

Dengue Fever-Dormant Projects, H1 2017 (Contd..3), H1 2017

Dengue Fever-Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Dengue Fever Therapeutic Products under Development, Key Players in Dengue Fever Therapeutics, Dengue Fever Pipeline Overview, Dengue Fever Pipeline, Dengue Fever Pipeline Assessment


Companies

Abivax SA

Altravax Inc

Biological Mimetics Inc

Bioneer Corp

Biotron Ltd

Emergent BioSolutions Inc

Ennaid Therapeutics LLC

GeneSegues Inc

GlaxoSmithKline Plc

Globavir Biosciences Inc

Griffith University

Hawaii Biotech Inc

Humabs BioMed SA

Immunotope Inc

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Merck & Co Inc

Molplex Ltd

NanoViricides Inc

Novartis AG

NovaTarg Therapeutics Inc

Panacea Biotec Ltd

Plex Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Sarepta Therapeutics Inc

SIGA Technologies Inc

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

Themis Bioscience GmbH

Visterra Inc

VLP Therapeutics LLC

Dengue Fever-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever-Pipeline Review, H1 2017, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape.

Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Dengue Fever-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 25, 22 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 5, 10 and 12 molecules, respectively.

Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 4

Dengue Fever-Overview 5

Dengue Fever-Therapeutics Development 6

Dengue Fever-Therapeutics Assessment 19

Dengue Fever-Companies Involved in Therapeutics Development 27

Dengue Fever-Drug Profiles 44

Dengue Fever-Dormant Projects 143

Dengue Fever-Discontinued Products 147

Dengue Fever-Product Development Milestones 148

Appendix 160


List Of Figure

List of Figures

Number of Products under Development for Dengue Fever, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Dengue Fever, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Dengue Fever-Pipeline by Abivax SA, H1 2017

Dengue Fever-Pipeline by Altravax Inc, H1 2017

Dengue Fever-Pipeline by Biological Mimetics Inc, H1 2017

Dengue Fever-Pipeline by Bioneer Corp, H1 2017

Dengue Fever-Pipeline by Biotron Ltd, H1 2017

Dengue Fever-Pipeline by Emergent BioSolutions Inc, H1 2017

Dengue Fever-Pipeline by Ennaid Therapeutics LLC, H1 2017

Dengue Fever-Pipeline by GeneSegues Inc, H1 2017

Dengue Fever-Pipeline by GlaxoSmithKline Plc, H1 2017

Dengue Fever-Pipeline by Globavir Biosciences Inc, H1 2017

Dengue Fever-Pipeline by Griffith University, H1 2017

Dengue Fever-Pipeline by Hawaii Biotech Inc, H1 2017

Dengue Fever-Pipeline by Humabs BioMed SA, H1 2017

Dengue Fever-Pipeline by Immunotope Inc, H1 2017

Dengue Fever-Pipeline by Indian Immunologicals Ltd, H1 2017

Dengue Fever-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Dengue Fever-Pipeline by Johnson & Johnson, H1 2017

Dengue Fever-Pipeline by Kineta Inc, H1 2017

Dengue Fever-Pipeline by Merck & Co Inc, H1 2017

Dengue Fever-Pipeline by Molplex Ltd, H1 2017

Dengue Fever-Pipeline by NanoViricides Inc, H1 2017

Dengue Fever-Pipeline by Novartis AG, H1 2017

Dengue Fever-Pipeline by NovaTarg Therapeutics Inc, H1 2017

Dengue Fever-Pipeline by Panacea Biotec Ltd, H1 2017

Dengue Fever-Pipeline by Plex Pharmaceuticals Inc, H1 2017

Dengue Fever-Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Dengue Fever-Pipeline by Sarepta Therapeutics Inc, H1 2017

Dengue Fever-Pipeline by SIGA Technologies Inc, H1 2017

Dengue Fever-Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Dengue Fever-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Dengue Fever-Pipeline by TechnoVax Inc, H1 2017

Dengue Fever-Pipeline by Themis Bioscience GmbH, H1 2017

Dengue Fever-Pipeline by Visterra Inc, H1 2017

Dengue Fever-Pipeline by VLP Therapeutics LLC, H1 2017

Dengue Fever-Dormant Projects, H1 2017

Dengue Fever-Dormant Projects, H1 2017 (Contd..1), H1 2017

Dengue Fever-Dormant Projects, H1 2017 (Contd..2), H1 2017

Dengue Fever-Dormant Projects, H1 2017 (Contd..3), H1 2017

Dengue Fever-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Dengue Fever Therapeutic Products under Development, Key Players in Dengue Fever Therapeutics, Dengue Fever Pipeline Overview, Dengue Fever Pipeline, Dengue Fever Pipeline Assessment


Companies

Abivax SA

Altravax Inc

Biological Mimetics Inc

Bioneer Corp

Biotron Ltd

Emergent BioSolutions Inc

Ennaid Therapeutics LLC

GeneSegues Inc

GlaxoSmithKline Plc

Globavir Biosciences Inc

Griffith University

Hawaii Biotech Inc

Humabs BioMed SA

Immunotope Inc

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Merck & Co Inc

Molplex Ltd

NanoViricides Inc

Novartis AG

NovaTarg Therapeutics Inc

Panacea Biotec Ltd

Plex Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Sarepta Therapeutics Inc

SIGA Technologies Inc

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

Themis Bioscience GmbH

Visterra Inc

VLP Therapeutics LLC